Our Team

Pinney Associates is pleased to announce the company’s new leadership team. Joe Gitchell is our new CEO, Lucy Owen is our new President, and Judy Ashworth has been promoted to Senior Vice President.

Pinney Associates’ founder, John Pinney, is now Founder and Chair.

Judy Ashworth, MD

Senior Vice President

Guiding the clinical development of CNS-active drugs in a challenging and rapidly evolving regulatory environment

Jack Henningfield, PhD

Vice President, Research, Health Policy, and Abuse Liability

Leading development and regulatory strategy for new treatments for neurological and psychiatric disorders with high unmet needs

August Buchhalter, PhD, MA

Director, Abuse Potential Assessment

Offering expertise in evaluating CNS-active drugs and abuse potential assessments

Ryan Lanier, PhD

Director, Clinical Development and Abuse Liability

Utilizing extensive clinical and nonclinical research experience to strategically guide the development of new CNS-active drugs

Michelle Ertischek, MPH

Director, Planning and Operations

Sustaining the links between clients and our dedicated project teams

Caitlyn Durgin

Bringing research experience to drug discovery and development

Marilyn Huestis, PhD

Senior Science and Policy Advisor, Clinical Pharmacology and Toxicology, Cannabinoid and Other CNS-Active Pharmacotherapies

Applying excellence in clinical and forensic toxicology to CNS-active drug and compound development and regulatory pathways

Jan Iles, MD, MPH

Senior Advisor, Clinical Development & Drug Safety

Providing innovative thinking and leadership in clinical development and pharmacovigilance

Sidney Schnoll, MD, PhD

Senior Advisor, Pharmaceutical Risk Management

Evaluating the benefit-risk balance of CNS-active drugs in postmarketing studies and REMS

Tom Huijbers, MS

Advisor, Regulatory Affairs

Developing state of the art global regulatory strategies

Marion Coe, PhD

Advisor, Clinical Development and Postmarketing Surveillance

Helping plan optimal pathways for the clinical development and postmarketing surveillance of unique and challenging classes of drugs

Rachel Beck, PhD

Advisor, Abuse-Deterrent Formulations

Enhancing understanding of the abuse potential of CNS-active drugs, from CMC and nonclinical assessments to postmarketing

Speak to an expert.